Is IQVIA Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IQVIA Holdings, Inc. moved from very expensive to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 29, an EV to EBITDA of 15.15, and a Price to Book Value of 6.50. In comparison, Laboratory Corp. of America Holdings has a P/E ratio of 29.20, while Quest Diagnostics, Inc. stands at 27.82, indicating that IQVIA is trading at a premium relative to its peers.
Despite a strong short-term performance, with a 1-week return of 3.22% compared to the S&P 500's 1.70%, the longer-term returns are concerning, particularly the 1-year return of -12.54% versus the S&P 500's 14.08%. This suggests that while IQVIA may have performed well recently, its overall valuation does not justify its current price level.